U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Structurally Diverse
Created
by admin
on Fri Jun 25 20:50:36 UTC 2021
Edited
by admin
on Fri Jun 25 20:50:36 UTC 2021
Source Materials Class ORGANISM
Source Materials Type VIRUS
Source Materials State LIVE ATTENUATED GENETICALLY MODIFIED
Organism Family ADENOVIRIDAE
Organism Genus MASTADENOVIRUS
Organism Species SIMIAN MASTADENOVIRUS E
Author NONE
Infraspecific Type RECOMBINANT VECTOR
Infraspecific Name ChAdOx1 nCoV-19
Part WHOLE
Record UNII
B5S3K2V0G8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD-1222
Common Name English
DNA (RECOMBINANT SIMIAN ADENOVIRUS OX1 .DELTA.E1E3 VECTOR HUMAN CYTOMEGALOVIRUS PROMOTER PLUS HUMAN TISSUE PLASMINOGEN ACTIVATOR SIGNAL PEPTIDE FUSION PROTEIN WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 ISOLATE WUHAN-HU-1 SPIKE GLYCOPROTEIN CODO
Systematic Name English
AZD1222
Common Name English
COVISHIELD
Brand Name English
OXFORD-ASTRAZENECA COVID VACCINE
Common Name English
CHADOX1 NCOV-19
Common Name English
Code System Code Type Description
CAS
2420395-83-9
Created by admin on Fri Jun 25 20:50:36 UTC 2021 , Edited by admin on Fri Jun 25 20:50:36 UTC 2021
PRIMARY
NCI_THESAURUS
C173021
Created by admin on Fri Jun 25 20:50:36 UTC 2021 , Edited by admin on Fri Jun 25 20:50:36 UTC 2021
PRIMARY
DRUG BANK
DB15656
Created by admin on Fri Jun 25 20:50:36 UTC 2021 , Edited by admin on Fri Jun 25 20:50:36 UTC 2021
PRIMARY
FDA UNII
B5S3K2V0G8
Created by admin on Fri Jun 25 20:50:36 UTC 2021 , Edited by admin on Fri Jun 25 20:50:36 UTC 2021
PRIMARY
Related Record Type Details
EXPRESSED PROTEIN->VECTOR
EXPRESSED PROTEIN->VECTOR
TARGET ORGANISM->VACCINE ANTIGEN
One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis
EFFICACY
Related Record Type Details
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
GENE DELETION CHIMPANZEE ADENOVIRUS E1 GENE SK3BO0EB8B
INSERTED GENE EXPRESSION VECTOR SITE_SPECIFIC UNSPECIFIED SUBSTANCE
eaa5aa8e
(not in database)